about
The prion hypothesis in Parkinson's disease: Braak to the futureInterface between tauopathies and synucleinopathies: A tale of two proteinsExcessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson DiseaseContemporary assessment and pharmacotherapy of Tourette syndromeMulticenter analysis of glucocerebrosidase mutations in Parkinson's disease.Proceedings of the Third Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies.Practical guidelines for managing adults with 22q11.2 deletion syndromeDeficits in the Mimicry of Facial Expressions in Parkinson's Disease.Vascular Parkinsonism: deconstructing a syndrome.Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis.Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's diseaseChanges in cortical and pallidal oscillatory activity during the execution of a sensory trick in patients with cervical dystoniaCrossroads in GDNF therapy for Parkinson's diseaseAssociation between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implicationsDystonia in progressive supranuclear palsyWhispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 genePhenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyRepetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series.Is there seasonal variation in risk of Parkinson's disease?Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate exportSerum urate as a predictor of clinical and radiographic progression in Parkinson disease.Mirror movements in parkinsonism: evaluation of a new clinical sign.Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD.Psychogenic facial movement disorders: clinical features and associated conditions.Longitudinal follow-up of SWEDD subjects in the PRECEPT StudyAntecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome.Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy.Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors.Apraxia in movement disorders.'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies?Pergolide associated cardiac valvulopathy based on Ontario administrative data.Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.Cardiac valvulopathy associated with pergolide use.The curious case of phenocopies in families with genetic Parkinson's disease.Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease.Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.Consensus statement on the diagnosis of multiple system atrophy.Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification.
P50
Q22001062-78188D43-AFE0-4402-A4FB-40A197AC0782Q22252940-B1098B91-A9CC-42BC-BE1D-1C4718C77D05Q23909232-2BD26192-966C-4FCD-A1E4-FC575480DCC4Q24607941-E385023D-DB4D-4522-A911-6D4700C96AB6Q24634577-5228B9D4-675E-4CE1-B4B1-FD286D68FE92Q26752608-CB434C5F-7C24-44B6-99EA-46E96EB49FD4Q27002798-4D5C5BC9-F36E-43C5-A849-2E96AAA64885Q27304616-936B66CE-63FA-4A89-80B2-9728CD93AFB3Q27333064-FA407088-B5DB-4CF0-B111-63575C1F4BB5Q27686808-11C098D4-2600-4AC8-A86E-EDB1FBEA9520Q28079852-286EB1D5-A568-430A-82DE-B1B9E848EB8BQ28277272-514EF48E-807A-4865-8977-15C77B8DC2D8Q28288749-9D23E8C6-AE06-41E0-987D-825376A8A678Q28296616-57341513-B279-4121-BC79-EAE8D945BA01Q28298135-7957BAF6-B22F-401D-9915-B2EF5F4F8524Q28379589-D666A1F0-A3EF-404C-8D65-ED1134F3CEFFQ29038345-F800F999-7C3A-4AA2-B47C-454C246224F9Q29614953-ED947E87-C5A8-4FEE-A05B-28AADE976EE7Q30300450-69BEADBA-252E-448D-A081-914E64C380CFQ30361489-9BF9C74E-B3B4-4C90-BC9A-634894C28A29Q30397541-1C04808A-2925-4DF2-AE60-A59BCC358458Q30440692-98962E32-EC2E-47CB-8303-9C9919623FB1Q30478585-A03FDB7F-CC29-4D04-9709-88C53D383006Q30498096-EB55E9F7-33DF-4854-BC4E-7BE3A1BC31CAQ30539108-DD7F1426-9F61-49B2-A297-8F14894CE48CQ30578973-2915FB22-68F6-4E29-AB17-389ED98315B6Q30585082-C071D6BF-C3AE-4F34-9EE4-D001968A1259Q30696088-A9E0A45B-172D-42E7-AF90-5690F6BA9218Q30922281-16C1D188-BDDF-49A4-A9D9-91E4638400BDQ30991143-137C0667-B835-4E2D-A004-BED9B2D471F4Q31128572-0729ED1B-786C-4D59-BBCA-D8822205544AQ31160159-FFDE8E22-30A2-40A4-B039-2F70716A179BQ33167532-AAFF4B94-8AFF-4164-996D-BC38F89CD807Q33238461-EADEED63-C0DC-4F28-B4DC-7E378D29432DQ33351731-5CED6D43-1A31-41A1-80CC-2274F8577A60Q33574373-1CA23740-2C0D-4C13-84CA-042C7D630450Q33590242-F760485E-51B7-429E-82E2-3762D7300F2AQ33602588-AD868DB1-7775-4B4D-A171-033D48172C52Q33605440-B69ADD50-57AA-4B58-A36F-DFB659B610AEQ33622086-95821B7D-29B2-4852-8D99-C1EE64C636B0
P50
description
Anthony E.T. Lang, MD, FRCPC, ...... ers Ctr., Toronto Western Hosp
@en
onderzoeker
@nl
հետազոտող
@hy
name
Anthony Lang
@ast
Anthony Lang
@en
Anthony Lang
@es
Anthony Lang
@nl
Anthony Lang
@sl
type
label
Anthony Lang
@ast
Anthony Lang
@en
Anthony Lang
@es
Anthony Lang
@nl
Anthony Lang
@sl
altLabel
A E Lang
@en
A Lang
@en
A. E. Lang
@en
A. Lang
@en
Anthony E Lang
@en
Anthony E. Lang
@en
Anthony E. Lang
@es
Anthony E. Lang
@sl
Lang A
@en
Lang A. E.
@en
prefLabel
Anthony Lang
@ast
Anthony Lang
@en
Anthony Lang
@es
Anthony Lang
@nl
Anthony Lang
@sl
P214
P244
P950
P106
P1153
36042140400
P1280
P1412
P21
P214
P244
P31
P4012
P496
0000-0003-1229-3667
P734
P735
P7859
lccn-n88045627